<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":2881,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280, 102 U.S.P.Q.2d 1729 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document fluid'>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/fcd395334c11872aa0a85ec182223ddd'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/fcd395334c11872aa0a85ec182223ddd'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1HMKCM003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HMKCM003">Previous Result: <span>Merenda v. Tabor, CIVIL ACTION NO. 5:10-...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1HMKCQ003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1HMKCQ003">Next Result: <span>Gresham v. City of Atlanta, CIVIL ACTION...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280, 102 U.S.P.Q.2d 1729 (Fed. Cir. 2012), Court Opinion'>
Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280, 102 U.S.P.Q.2d 1729 (Fed. Cir. 2012),...
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280, 102 U.S.P.Q.2d 1729 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1HMJKG003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Otsuka Pharmaceutical Co. v. Sandoz, Inc.</div>
<div class='displayCitation'>102 U.S.P.Q.2d 1729</div>
<div class='displayCitation'>2012 BL 111335</div>
<div class='displayCitation'>678 F.3d 1280</div>
<div class='displayCitation'>bna a0d1v6a6w6</div>
<div class='displayCitation'>bna a0d1x0k9t7</div>
<div class='displayCitation'>bna a0d3d5m8y9</div>
<div class='displayCitation'>wkffecase:26060616</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1HMJKG003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280, 102 U.S.P.Q.2d 1729 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Otsuka Pharmaceutical Co. v. Sandoz, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1HMJKG003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1HMJKG003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1HMJKG003" /><input id="title" name="title" type="hidden" value="Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280, 102 U.S.P.Q.2d 1729 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="fcd395334c11872aa0a85ec182223ddd" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1HMJKG003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2Ffcd%33%39%35%33%33%34c%31%31%38%37%32aa%30a%38%35ec%31%38%32%32%32%33ddd%2Fdocument%2FX%31HMJKG%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/bcite/X1HMJKG003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/bcite/X1HMJKG003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/bcite/X1HMJKG003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/related_content/X1HMJKG003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=true;
  //]]>
</script>

<table cellpadding='0' cellspacing='0' class='hasSearchTerms ' id='fluidHolder'>
<tr>
<td align='right' class='fluidLeftColumn' valign='top' width='100%'>
<div class='documentContent hasSearchTerms ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1707908530179";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">678 F.3d 1280</div>
<div class="cite" data-cite-type="ReporterOfDecisions">102 U.S.P.Q.2d 1729</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 2011-1126, 2011-1127.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 111335</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
OTSUKA PHARMACEUTICAL CO., LTD., Plaintiff-Appellee, v. SANDOZ, INC.,
Sun Pharmaceutical Industries, Ltd., Synthon BV, Synthon Holdings BV,
Synthon Laboratories, Inc., and Synthon Pharmaceuticals, Inc.,
Defendants, and Apotex Inc. and Apotex Corp., Defendants-Appellants, and
Teva Pharmaceuticals USA, Inc., Barr Laboratories, Inc., and Barr
Pharmaceuticals, Inc., Defendants-Appellants.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 2011-1126, 2011-1127.
</center></p>
<p><center>
May 7, 2012.
</center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914838" href="#headnote_ref_pq2-dec_914838">[1]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.01" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.01">&#9658;115.0903.01</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnote_text">
&ldquo;Lead compound&rdquo; analysis is properly employed in determining third factor in obviousness analysis, which examines differences between claimed invention and prior art, if new chemical compound is created from attempts to improve on prior art compounds rather than from theoretical considerations; in actions in which parties' arguments focus on selecting and modifying particular prior art compounds, test for whether new chemical compound would have been prima facie obvious over particular prior art ordinarily follows two-part inquiry that first determines whether chemist of ordinary skill in art would have selected asserted prior art compounds as starting points for further development efforts, and then determines whether prior art would have supplied skilled artisan with reason or motivation to modify those lead compounds to make claimed compound with reasonable expectation of success.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914839" href="#headnote_ref_pq2-dec_914839">[2]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court, in determining whether invention of patent claiming carbostyril derivatives as antipsychotic compounds is invalid for obviousness, did not err in concluding that compounds clozapine and risperidone would have been considered viable lead compounds for further development efforts, since district court did not require that &ldquo;only the most obvious choice&rdquo; could be considered lead compound, since clozapine and risperidone were only antipsychotics on market at time inventors began work, and thus were obvious and natural lead compounds whose structures persons of ordinary skill in art would have considered to modify to obtain improved antipsychotic compounds, since there were no carbostyril compounds at that time that were marketed as antipsychotics or publicly known to have potent antipsychotic activity with minimal side effects, and since carbostyrils therefore were not plausible lead compounds, except in retrospect.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914840" href="#headnote_ref_pq2-dec_914840">[3]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court correctly determined that person of ordinary skill in art would not have selected &ldquo;unsubstituted butoxy&rdquo; of prior art patent as lead compound in developing invention of patent in suit, which claims carbostyril derivatives as antipsychotic compounds, since claims of prior patent explicitly disclose unsubstituted butoxy as producing antihistaminic effect, and this clear teaching controls over prior patent's far more nebulous disclosure that &ldquo;trillions&rdquo;
of carbostyril compounds encompassed by that patent &ldquo;have antihistaminic and central nervous controlling effects,&rdquo; and since prior art declaration disclosing data from tests of nine carbostyril compounds shows that potency of unsubstituted butoxy was inferior to that of four structurally dissimilar test compounds that were all &ldquo;propoxy-linked,&rdquo;
unlike &ldquo;butoxy-linked&rdquo; compound of patent in suit.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914841" href="#headnote_ref_pq2-dec_914841">[4]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court correctly determined that person of ordinary skill in art would not have selected &ldquo;2,3 dichloro propoxy&rdquo; compound of prior art application as lead compound in developing invention of patent in suit, which claims carbostyril derivatives as antipsychotic compounds, since infringement defendants failed to show that generic disclosure of application provided &ldquo;ample motivation&rdquo; to narrow prior art genus, or that application predicted results disclosed in patent in suit; defendants' &ldquo;bracketing theory,&rdquo; which asserts that skilled artisan would have combined prior art &ldquo;unsubstituted butoxy&rdquo; and 2,3 dichloro propoxy compounds to arrive at compound sharing some structural features of both, constituted improper hindsight analysis.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914842" href="#headnote_ref_pq2-dec_914842">[5]</a> <span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnote_text">
Federal district court correctly determined that person of ordinary skill in art would not have selected prior-art &ldquo;OPC-4392&rdquo;
compound as lead compound in developing invention of patent in suit, which claims carbostyril derivatives as antipsychotic compounds, even though OPC-4392 was described as &ldquo;anti-psychotic drug&rdquo; in prior art journal, and proceeded to &ldquo;Phase II&rdquo; clinical trials, since prior art, taken as whole, shows that skilled artisan would have concluded that compound did not treat positive symptoms of schizophrenia, that it was viewed as lacking &ldquo;antipsychotic component,&rdquo; that drug was likely to cause patients to act out their delusions and hallucinations, and that it caused &ldquo;severe&rdquo; side effects at low doses, and since prior art thus taught away from using OPC-4392 as starting point for further antipsychotic research; even if it is assumed that OPC-4392 would have been selected as lead compound, defendants failed to prove that prior art would have directed skilled artisan to make various modifications necessary to convert OPC-4392 into claimed compound, since defendants arguments rely largely on inventors' and plaintiff's own development efforts, which is impermissible hindsight reasoning.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914843" href="#headnote_ref_pq2-dec_914843">[6]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Double patenting </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0708" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0708">&#9658;115.0708</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; In general </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.01" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.01">&#9658;115.0903.01</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Nonstatutory obviousness-type double patenting, in case involving claimed chemical compounds, differs in important ways from failure to meet nonobviousness requirement under 35 U.S.C. &sect;103, since patent principally underlying double patenting rejection need not be prior art, and since, in analyzing double patenting, issue is not whether person of ordinary skill in art would have selected earlier compound as lead compound, in that analysis must necessarily focus on earlier claimed compound over which double patenting has been alleged, whether or not it is lead compound; question of whether prior art would have supplied motivation to modify earlier compound is relevant to obviousness-type double patenting analysis, since that analysis, like analysis under Section 103, entails determining, among other things, whether skilled artisan would have had reason or motivation to modify earlier claimed compound to make compound of asserted claim with reasonable expectation of success.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<a name="headnote_pq2-dec_914844" href="#headnote_ref_pq2-dec_914844">[7]</a> <span>Patentability/Validity &mdash; Anticipation &mdash; Double patenting </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0708" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0708">&#9658;115.0708</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Patentability/Validity &mdash; Obviousness &mdash; Relevant prior art &mdash; Particular inventions </span> <a href="http://www.bloomberglaw.com/document/1707908530179/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.0903.03" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.0903.03">&#9658;115.0903.03</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_9" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_9" class="headnoteContent"></div>
<div class="headnote_text">
Asserted claims for carbostyril derivative aripiprazole, used as antipsychotic compound, are not invalid for nonstatutory obviousness-type double patenting over prior patent claiming &ldquo;unsubstituted butoxy&rdquo;
compound, since aripiprazole, which has chlorine substituents at 2-
and 3-positions of its phenyl ring, differs structurally from unsubstituted butoxy, which has hydrogens at those positions, since evidence demonstrating high degree of unpredictability in antipsychotic drug discovery as of priority date supports finding that prior art disclosures regarding unsubstituted butoxy did not teach person of ordinary skill in art to pursue 2,3 dichloro substitution on its phenyl ring to achieve antipsychotic activity, and since evidence indicates that substitution with chlorine atoms at 2- and 3-positions of phenyl ring of unsubstituted butoxy would not have been &ldquo;logical and routine&rdquo; modification at time of invention.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
District of New Jersey, Mary L. Cooper, J., [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324.
</p></div>
<span CLASS="page_no" data-cite="678 f 3d 1281" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1281" data-primary-citation="678 F.3d 1280">[*1281]</span> <div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="678 f 3d 1282" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1282" data-primary-citation="678 F.3d 1280">[*1282]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="102 uspq 2d 1731" data-cite-type="ReporterOfDecisions" data-cite-pageno="1731" data-primary-citation="102 U.S.P.Q.2d 1729">[**1731]</span> <span CLASS="page_no" data-cite="678 f 3d 1283" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1283" data-primary-citation="678 F.3d 1280">[*1283]</span> 
</p></div>
</div>
<div id="para2" printdualcolumn="true"><p>
  James B. Monroe, Finnegan, Henderson, Farabow, Garrett
&amp; Dunner, LLP, of Washington, DC, argued for
plaintiff-appellee. With him on the brief were Michael J.
Flibbert, Paul M. Browning and Denise Main. Of counsel on the
brief were Robert L. Baechtold and John D. Murnane,
Fitzpatrick, Cella, Harper &amp; Scinto, of New York, New York.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Steven E. Feldman, Husch Blackwell LLP, of Chicago, IL, argued
for Defendants-Appellants Apotex Inc., et al. With him on the
brief were Daniel R. Cherry and Sherry L. Rollo.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Elizabeth J. Holland, Kenyon &amp; Kenyon LLP, of New York, NY,
for defendants-appellants Teva Pharmaceuticals USA, Inc., et
al. With her on the brief was Maria Luisa Palmese.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before LOURIE, MOORE, and REYNA, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  LOURIE, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Apotex Inc., Apotex Corp., Teva Pharmaceuticals USA, Inc.,
Barr Laboratories, Inc., and Barr Pharmaceuticals, Inc.
(collectively, the `'Defendants") appeal from the final
decision of the United States District Court for the District
of New Jersey sustaining the validity of the asserted claims of
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X2G00C5120J?jcsearch=usp%205006528&amp;summary=yes#jcite">U.S. Patent 5,006,528</a> (the `"<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X2G00C5120J?jcsearch=usp%205006528&amp;summary=yes#jcite">528 patent</a>") under
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a> and under the doctrine of nonstatutory double patenting. We
affirm.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Schizophrenia is a debilitating mental disease affecting about
one percent of the human population. Despite extensive
research, the cause, mechanism, and etiology of schizophrenia
remain unknown. Individuals with schizophrenia suffer from
positive symptoms, negative symptoms, and cognitive deficits.
Positive symptoms include hallucinations and delusions.
Negative symptoms include flat affect, poverty
<span CLASS="page_no" data-cite="678 f 3d 1284" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1284" data-primary-citation="678 F.3d 1280">[*1284]</span> 
of speech, inability to experience pleasure, lack of desire
to form relationships, and lack of motivation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Drugs that treat schizophrenia are called antipsychotics. The
first antipsychotic drug, chlorpromazine, was discovered by
accident in the early 1950s. Subsequent research revealed that
chlorpromazine's antipsychotic properties were due to its
antagonism (blocking) of dopamine receptors in the brain. That
finding resulted in the development of other "typical"
antipsychotics, which treat positive symptoms but not negative
symptoms and have a number of problematic side effects,
including extrapyramidal symptoms ("EPS"), tardive dyskinesia,
prolactin elevation (hyperprolactinemia), <span CLASS="page_no" data-cite="2012 bl 111335 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> and sudden decrease
in blood pressure (orthostatic hypotension). The United States
Food and Drug Administration ("FDA") last approved a typical
antipsychotic in 1975. Despite their drawbacks, typical
antipsychotics are still used today.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Researchers discovered clozapine in the early 1960s. Clozapine
was the first "atypical" antipsychotic, in that it had a
diminished propensity to cause EPS and was useful for treating
both positive and negative symptoms of schizophrenia. Clozapine
had serious potential side effects, however, including
orthostatic hypotension, frank hypotension, and agranulocytosis
(a life-threatening decrease in white blood cells). Due to
those side effects clozapine was withdrawn from clinical trials
in the 1970s, prompting scientists to seek an atypical
antipsychotic drug similar to clozapine with respect to
efficacy but lacking its toxicity and side effects.
Researchers' efforts were largely unsuccessful, however, and
the FDA approved no new antipsychotic drugs between 1976 and
1989. The FDA finally approved clozapine in 1990, but only for
treatment-resistant or treatment-intolerant patients, subject
to rigorous blood testing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The FDA approved risperidone, the first postclozapine atypical
antipsychotic, in 1994. Since then the FDA has approved seven
other atypical antipsychotics: olanzapine (1996); quetiapine
(1997); ziprasidone (2001); aripiprazole (2002); paliperidone
(2007); asenapine (2009); and iloperidone (2009). Although
clozapine remains the "gold standard" with respect to efficacy,
the other atypical antipsychotics are considered at least as
effective as typical antipsychotics for treating positive
symptoms, while also treating negative symptoms and causing
fewer EPS side effects. Every FDA-approved atypical
antipsychotic has a chemical structure related either to
clozapine or risperidone, with the sole exception of
aripiprazole &mdash; the compound at issue in the present
appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Aripiprazole is the active ingredient in the antipsychotic drug
marketed by Otsuka Pharmaceutical Co., Ltd. ("Otsuka") under
the brand name Abilify&reg;. The culmination of several decades
of drug development efforts, Abilify&reg; was approved in 2002
by the FDA and is marketed for the treatment of schizophrenia,
bipolar disorder, irritability associated with autistic
dis-order in pediatric patients, and as an addon treatment for
depression. Abilify&reg; has been commercially successful;
since 2005 its annual sales have exceeded a billion dollars,
and in 2009 its sales were $3.3 billion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Aripiprazole has the chemical name 7-(4-[4-(2,
3-dichlorophenyl)-1-piperazinyl]-butoxy)-3,4-dihydrocarbostyril
and has the following chemical structure:
<span CLASS="page_no" data-cite="102 uspq 2d 1732" data-cite-type="ReporterOfDecisions" data-cite-pageno="1732" data-primary-citation="102 U.S.P.Q.2d 1729">[**1732]</span> <span CLASS="page_no" data-cite="678 f 3d 1285" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1285" data-primary-citation="678 F.3d 1280">[*1285]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1HMJKG003?documentName=68395_a">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                              <b>aripiprazole</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Otsuka Pharm. Co. v. Sandoz, Inc.</i>, No. 3:07-cv-1000,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *4-5, <a>2010 U.S. Dist. LEXIS 132595</a>, at *15
(D.N.J. Nov. 15, 2010). Aripiprazole is a "carbostyril
derivative," that is, its chemical structure contains a
quinolinone fused ring (labeled as "3,4-dihydrocarbostyril" in
the structure above). Aripiprazole's carbostyril ring is
referred to as "3,4-dihydro" because it has two hydrogen atoms
(not shown in the structure <span CLASS="page_no" data-cite="2012 bl 111335 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> above) connected to the 3 and 4
positions, and thus has a single bond between these two carbon
atoms. In contrast, a "carbostyril" moiety has only one
hydrogen atom at the 3 and 4 positions and a resulting double
bond between the carbon atoms. Researchers refer to both
variants as "carbostyril derivatives." Connected to the
7-position of aripiprazole's carbostyril core is a "butoxy
linker" consisting of four methylene (-CH2-) units. A "propoxy
linker," in contrast, consists of only three methylene units.
Connected to aripiprazole's butoxy linker is a piperazine ring
and a phenyl ring. The terminal phenyl ring of aripiprazole is
"2,3-dichloro" substituted, meaning that it has chlorine atoms
connected to the 2 and 3 positions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Otsuka is the assignee of the &prime;<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X2G00C5120J?jcsearch=usp%205006528&amp;summary=yes#jcite">528 patent</a>, which has a
foreign priority date of October 31, 1988, was filed on October
20, 1989, and issued on April 9, 1991. The exclusivity afforded
by the &prime;<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X2G00C5120J?jcsearch=usp%205006528&amp;summary=yes#jcite">528 patent</a>, including a five-year patent term
extension and a six-month period of pediatric exclusivity, will
expire on April 20, 2015. <i><cite>Id</cite>.</i> at *4,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 U.S. Dist. LEXIS 132595 at *14. Claim 12 of the &prime;528 patent claims
aripiprazole using its chemical name. &prime;528 patent col.19
ll.18-19. Claim 16 claims "[a] pharmaceutical composition for
treating schizophrenia containing, as the active ingredient, a
carbostyril compound . . .," <i>id.</i> col.19 ll.16-col.20
1.3, and claim 17 claims "[t]he pharmaceutical composition of
claim 16 wherein the carbostyril compound" is aripiprazole,
<i>id.</i> col.20 ll.4-7. Claim 23, which was added during
re-examination of the &prime;528 patent, claims a method of
treating schizophrenia comprising administering a
pharmaceutical composition containing aripiprazole as an active
ingredient. Ex Parte Reexamination Certificate, &prime;528
patent col.2 LL.13-16.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Defendants and several other companies submitted
Abbreviated New Drug Application ("ANDA") filings to the FDA
for approval to engage in the commercial manufacture, use, or
sale of generic aripiprazole products. Otsuka brought actions
against these generic drug manufacturers for patent
infringement; most of those actions were consolidated into the
case
<span CLASS="page_no" data-cite="678 f 3d 1286" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1286" data-primary-citation="678 F.3d 1280">[*1286]</span> 
now before us on appeal. <i>See Otsuka</i>,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *1, <a>2010 U.S. Dist. LEXIS 132595</a>, at *3-5. Otsuka
asserted that the Defendants infringed claims 12, 17, and 23 of
the &prime;528 patent under <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEJ04O003?jcsearch=35%20U.S.C.%20%20271(e)(2)(A)&amp;summary=yes#jcite">35 U.S.C. &sect; 271</a>(e)(2)(A). The
Defendants conceded that their ANDA filings constituted literal
infringement but asserted in defense and counterclaimed that
the claims were invalid for obviousness and obviousness-type
double patenting.<a HREF="#fn100" name="fnref_fn100">[fn1]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court held a bench trial from August 5 through
August 26, 2010, and heard <span CLASS="page_no" data-cite="102 uspq 2d 1733" data-cite-type="ReporterOfDecisions" data-cite-pageno="1733" data-primary-citation="102 U.S.P.Q.2d 1729">[**1733]</span> closing arguments on October 21,
2010. The court entered its Amended Memorandum Opinion on
December 15, 2010. <i>See <cite>id</cite>.</i> at *1,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 U.S. Dist. LEXIS 132595 at *5.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On the issue of obviousness under &sect; 103, the court
concluded that the Defendants failed to prove by clear and
convincing evidence that the asserted claims would have been
obvious to one of ordinary skill. In its analysis, the court
considered the known carbostyril derivatives, with particular
emphasis on the three purported "lead compounds" asserted by
the Defendants. <i>Id.</i> at *17,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 U.S. Dist. LEXIS 132595 at *53.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The first of the Defendants' alleged lead compounds is
7-[4-(4-<span CLASS="page_no" data-cite="2012 bl 111335 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> phenylpiperazinyl)-butoxy]-3,4-dihydrocarbostyril,
which has the following chemical structure:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1HMJKG003?documentName=68395_b">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                         <b>"unsubstituted butoxy"</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Br. Defs.-Appellants Apotex, at 12. The parties refer to this
compound as the "un-substituted butoxy," because its phenyl
ring is unsubstituted and it has a butoxy linker connecting the
7-position of its carbostyril core to its piperazine ring.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The unsubstituted butoxy is disclosed and claimed in Otsuka's
earlier U.S. Patent 4,734,416 (the `"416 patent"), which the
parties agree is prior art to the &prime;528 patent. The
&prime;416 patent issued on March 29, 1988, and expired on
March 29, 2005. Entitled "Pharmaceutically Useful Carbostyril
Derivatives," the &prime;416 patent teaches a broad genus
encompassing "approximately nine trillion compounds."
<i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *3,
<a>2010 U.S. Dist. LEXIS 132595</a>, at *12. The &prime;416 patent discloses that
"[c]arbostyril derivatives having antihistaminic action and
central nervous controlling action are useful as antihistaminic
agents or central nervous controlling agents." &prime;416
patent abstract. The patent further discloses that the
compounds:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  are useful for central nervous controlling agents such
  as central muscle relaxing agents, sleep-inducing
  agents, pre-operative drugs, antischizophrenia agents,
  sedatives, antianxiety drugs, antimanic depressive
  psychosis agents, antipyretic agents, analgetic agents
  and depressors, without showing side-effects such as
  the feeling of thirst, constipation, tachycordia
  [sic], parkinsonism, and/or delayed dyscinesia [sic]
  which exist with conventional central nervous
  controlling agents.
<span CLASS="page_no" data-cite="678 f 3d 1287" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1287" data-primary-citation="678 F.3d 1280">[*1287]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Id.</i> col.3 ll.14-22. Claim 13 of the &prime;416 test
for "Activity for inhibiting jumping patent claims the
unsubstituted butoxy using its chemical name. <i>Id.</i>
col.70 ll.62-63. Claim 50 claims "[a] method of producing an
antihistaminic effect in a mammal comprising the step of
administering to the mammal for producing said antihistaminic
effect a pharmaceutical composition containing a suitable
amount of a carbostyril derivative" having a general chemical
formula, <i>id.</i> col.76 ll.1-60, and claim 116 claims
"[t]he method of claim 50, wherein the carbostyril derivative
is selected from the group consisting of nine specific
carbostyril derivatives, including the unsubstituted butoxy,
<i>id.</i> col.84 ll.29-16.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The unsubstituted butoxy is also disclosed in a declaration
submitted during the prosecution of the &prime;416 patent by
one of that patent's co-inventors, Dr. Kazuyuki Nakagawa (the
"Nakagawa declaration"). J.A. 3792-3807. The Nakagawa
declaration discloses three sets of test data comparing certain
carbostyril derivatives. The first two measure the compounds'
antihistaminic activity. The third involves a behavior in mouse
induced by Methamphetamine and LDOPA." J.A. 3803. Although the
Nakagawa declaration nowhere mentions schizophrenia or
antipsychotic activity, and despite conflicting evidence
regarding the use of mouse jumping test data in antipsychotic
drug discovery, the district court found <span CLASS="page_no" data-cite="102 uspq 2d 1734" data-cite-type="ReporterOfDecisions" data-cite-pageno="1734" data-primary-citation="102 U.S.P.Q.2d 1729">[**1734]</span> that Dr. Nakagawa's
mouse jumping data "could be indicative of potential
antipsychotic activity to the skilled artisan."
<i>Otsuka<span CLASS="page_no" data-cite="2012 bl 111335 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> </i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *10,
<a>2010 U.S. Dist. LEXIS 132595</a>, at *34.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Nakagawa declaration provides mouse jumping test data for
nine carbostyril derivative test compounds and two prior art
reference compounds. The potency of the compounds is indicated
with an effective dosage ("ED <sub>50</sub>) value measured in
milligrams per kilogram, wherein a lower value indicates
greater potency in the mouse jumping test. The following table
summarizes the data for the test compounds.
</p></div>
<pre>
____________________________________________________________________________________________________________________________________
<b>Compound No.                               Chemical Name                                                   ED</b><sub>50</sub>
____________________________________________________________________________________________________________________________________
        5             5-[3-(4-phenylpiperazinyl)propoxy]-3, 4-dihydrocarbostyri] dihydrochloride                2.1
____________________________________________________________________________________________________________________________________
        6             7-[3-(4-phenylpiperazinyl)propoxy]-3, 4-dihydrocarbostyril dihydrochloride                9.3
____________________________________________________________________________________________________________________________________
       16             7-{3-[4-(4-chlorophenyl)piperazinyl]propoxy}-3, 4-dihydrocarbostyril                     15.1
       39             7-{3-[4-(3-chlorophenyl)piperazinyl]propoxy}-3, 4-dihydrocarbostyril                       2.5
____________________________________________________________________________________________________________________________________
       41             7-[4-(4-phenyl-1-piperazinyl)butoxy]-3, 4-dihydrocarbostyri] ("unsubstituted butoxy")     5.5
       42             1-methyl-7-[3-(4-phenyl-1-piperazinyl)propoxy]-3, 4-dihydrocarbostyril                   10.7
____________________________________________________________________________________________________________________________________
       43             7-{3-[4-(2-chlorophenyl)-1-piperazinyl]propoxy}-3,4-dihydrocarbostyril                    3.4
____________________________________________________________________________________________________________________________________
       44             5-{3-[4-(2-ethoxyph enyl)-1-piperazinyl]propoxy}-3,4-dihydrocarbostyril                  0.53
____________________________________________________________________________________________________________________________________
       45             [4-(4-methylphenyl)-1-piperazinyl]propoxy}-3, 4-dihydrocarbostyril                        8.1
____________________________________________________________________________________________________________________________________
</pre>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  J.A. 3794, 3796, 3805. The two most potent carbostyril
derivatives tested in the mouse jumping study have a 5-propoxy
linker, <i>i.e.</i>, a propoxy substituent connected at the
5-position of the carbostyril core. Compound 44, the most
potent derivative with an ED <sub>50</sub> of 0.53, has a
5-propoxy linker and an ethoxy substituent (-OCH<sub>2</sub>
CH<sub>3</sub>) at the 2-position of its phenyl ring. Compound
5, the second most potent derivative
<span CLASS="page_no" data-cite="678 f 3d 1288" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1288" data-primary-citation="678 F.3d 1280">[*1288]</span> 
with an ED <sub>50</sub> of 2.1, has a 5-propoxy linker and
an unsubstituted phenyl ring. Of the 7-linked <span CLASS="page_no" data-cite="2012 bl 111335 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> carbostyril
derivatives for which Dr. Nakagawa provided mouse jumping data,
Compound 39, a 3-chloro substituted propoxy,<a HREF="#fn200" name="fnref_fn200">[fn2]</a> had an ED
<sub>50</sub> of 2.5; Compound 43, a 2-chloro substituted
propoxy, had an ED <sub>50</sub> of 3.4; Compound 41, the
unsubstituted butoxy, had an ED <sub>50</sub> of 5.5; Compound
6, an unsubstituted propoxy, had an ED <sub>50</sub> of 9.3;
and Compound 16, a 4-chloro substituted propoxy, had an ED
<sub>50</sub> of 15.1. Thus, the best compounds in this test
were the propoxys, not the butoxy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The second alleged lead compound considered by the district
court is a carbostyril derivative with the chemical name
7-(3-[4-(2,3-dichlorophenyl)-1-piperazinyl]-propoxy)3,4-dihydro
carbostyril and the chemical structure depicted below:
<span CLASS="page_no" data-cite="102 uspq 2d 1735" data-cite-type="ReporterOfDecisions" data-cite-pageno="1735" data-primary-citation="102 U.S.P.Q.2d 1729">[**1735]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1HMJKG003?documentName=68395_c">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                         <b>"2,3-dichloro propoxy"</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Br. Defs.-Appellants Apotex, at 9. The parties refer to this
compound as the "2,3-dichloro propoxy" because its phenyl ring
is substituted with a chlorine atom at the 2 and 3 positions
and it has a propoxy linker connecting its carbostyril core and
its piperazine ring. The 2,3-dichloro propoxy was disclosed in
two prior art foreign counterparts to Otsuka's &prime;416
patent: German Patent 2,912,105 (the "DE &prime;105 patent"),
J.A. 3808-930, at 3926 (example 317); and Swedish Patent
Publication 434,-945 (the "SE &prime;945 application"), J.A.
6396-565, at 6556 (example 134). Like the &prime;416 patent,
the SE &prime;945 application teaches that its carbostyril
derivatives "can be used as antihistamines or agents having a
regulating action in the central nervous system," J.A. 6495,
and discloses numerous examples of agents in the latter
category:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The compounds according to the present invention are
  therefore useful as means of controlling the central
  nervous system as muscle relaxants, sleeping agents,
  presurgery drugs, antischizophrenia agents, sedatives,
  anxiolytics, drugs for manic-depressive psychosis,
  fever-lowering agents, analgesics and "depressors"
  without showing side effects such as thirst,
  constipation, tachycardia, parkinsonism and/or delayed
  dyschezia, which are displayed by conventional agents
  which act on the central nervous system.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 6499. The SE &prime;945 application "discloses dozens of
carbostyril compounds," and the 2,3-dichloro propoxy "is just
one of ninety-six different compounds disclosed in Example 134
alone." <i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *11,
<a>2010 U.S. Dist. LEXIS 132595</a>, at *37-38. The DE &prime;105 patent "is
substantially the same as the SE &prime;945 application except
that the DE &prime;105 Patent omits any mention of potential
antipsychotic activity." <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id</a>.</i> at *12,
<a>2010 U.S. Dist. LEXIS 132595</a> at *38.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The final purported lead compound considered by the district
court is OPC-4392. This carbostyril derivative, which has the
following chemical structure, has a 2,3-dimethyl
<span CLASS="page_no" data-cite="678 f 3d 1289" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1289" data-primary-citation="678 F.3d 1280">[*1289]</span> 
substituted phenyl ring, a propoxy linker, and a
carbostyril ring containing a double bond at the 3, 4-position:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1HMJKG003?documentName=68395_d">Exhibit</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               <b>"OPC-4392"</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Br. Defs.-Appellants Apotex, at 10. OPC-4392 is an Otsuka
development compound and, as of the priority date of the
&prime;528 patent, was the only carbostyril derivative tested
in humans as a potential antipsychotic. A prior art
article published in 1987 describes OPC-4392 as "a totally new compound
that is an anti-psychotic drug being developed." Mitsukuni
Murasaki, <i>New Psycho-Neuro Agents</i>,
16 Japanese <span CLASS="page_no" data-cite="2012 bl 111335 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> J. Clinical Psychiatry 1515, 1517 (<span CLASS="page_no" data-cite="102 uspq 2d 1736" data-cite-type="ReporterOfDecisions" data-cite-pageno="1736" data-primary-citation="102 U.S.P.Q.2d 1729">[**1736]</span> 1987) ("Murasaki 1987"); J.A.
5891-919, at 5907. The Murasaki 1987 article further notes that
"the anti-psychotic action was not strong but the strength of
the activating action stood out," that "improvements were
observed in the negative symptoms," and that "the
extra-pyramidal disturbances are extremely weak." J.A. 5907. A
prior art publication from January 1988 by the same author
stated that OPC-4392 was "expected to have some advantageous
effects different from those of conventional antipsychotic
drugs," such as chlorpromazine. Mitsukuni Murasaki, <i>Phase</i>
<i>1 Study of a New Antipsychotic Drug, OPC-4392</i>,
12 Progress Neuro-Psychopharmacology &amp; Biological Psychiatry 793, 802
(1988) ("Murasaki 1988"); J.A. 10396-406, at 10405. Although
the article stated that OPC-4392 was "expected to have fewer
side effects than conventional drugs of the same class," it
also reported that subjects receiving a 5-milligram dose of
OPC-4392 "experienced sleeplessness, stagger, weakness,
fatigability, heavy headedness, lack of motivation and
disturbed concentration, which were so severe that they were
not able to perform daily routine work." J.A. 10397, 10401.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Evaluating the differences between the claimed invention and
the prior art, the district court found that the asserted prior
art did not teach one of ordinary skill to select the
unsubstituted butoxy, the 2,3-dichloro propoxy, or OPC-4392 as
a lead compound for further antipsychotic research.
<i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *18-19, *20, *22,
<a>2010 U.S. Dist. LEXIS 132595</a>, at *59, *64, *70. Rather, the court
found that a structure like clozapine or risperidone &mdash;
both of which are structurally dissimilar to aripiprazole
&mdash; would have been an attractive lead compound.
<i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id</a>.</i> at *23-24, <a>2010 U.S. Dist. LEXIS 132595</a> at *76.
The court thus concluded that the Defendants failed to prove by
clear and convincing evidence that one of ordinary skill would
have been motivated to combine the asserted prior art to make
aripiprazole and would have had a reasonable expectation of
success in doing so. <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id</a>.</i> at *23-24,
<a>2010 U.S. Dist. LEXIS 132595</a> at *76-77.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The court then turned to the issue of nonstatutory
obviousness-type double patenting. The court considered whether
aripiprazole and its uses are not patentably distinct from the
unsubstituted butoxy in claim 13 of the &prime;416 patent.
<i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id., at *27-28</a>,
<span CLASS="page_no" data-cite="678 f 3d 1290" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1290" data-primary-citation="678 F.3d 1280">[*1290]</span> 
<a>2010 U.S. Dist. LEXIS 132595</a> at *88. Noting the
structural differences between aripiprazole and the
unsubstituted butoxy, the court found that the prior art did
not teach one of ordinary skill to achieve antipsychotic
activity by modifying the un-substituted butoxy with a
2,3-dichloro substitution on its phenyl ring to make
aripiprazole. <i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id. at *28-29</a>,
<a>2010 U.S. Dist. LEXIS 132595</a>
at *90-91. The court thus concluded that the Defendants
failed to prove by clear and convincing evidence that the
asserted claims were invalid for nonstatutory double patenting.
<i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id. at *29</a>, <a>2010 U.S. Dist. LEXIS 132595</a> at *92.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On December 15, 2010, the court entered its Amended Order and
Final Judgment in favor of Otsuka. <i>Otsuka Pharm. Co. v.</i>
<i>Sandoz, Inc.</i>, No. 3:07-cv-1000, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324
(D.N.J. Nov. 15, 2010). The Defendants timely appealed. We have
jurisdiction pursuant to <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A patent is invalid if an alleged infringer proves, by clear
and convincing evidence, that the differences <span CLASS="page_no" data-cite="2012 bl 111335 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> between the
claimed subject matter and the prior art are such that the
subject matter as a whole would have been obvious at the time
the invention was made to a person having ordinary skill in the
pertinent art. <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect;&sect; 103</a>(a), <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEJ050003?jcsearch=35%20U.S.C.%20%20282(2)&amp;summary=yes#jcite">282</a>(2); <i>Microsoft</i>
<i>Corp. v. i4i Ltd.</i>, <cite>___ U.S. ___</cite>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">131 S.Ct. 2238</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1FI916003?jcsearch=131%20supreme%20court%202238&amp;summary=yes#jcite">2242</a>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1FI916003?jcsearch=180%20l%20ed%202d%20131&amp;summary=yes#jcite">180 L.Ed.2d 131</a> (2011). Obviousness is a question of law with
underlying factual findings, including: (1) the scope and
content of the prior art; (2) the level of ordinary skill in
the pertinent art; (3) the differences between the claimed
invention and the prior art; and (4) objective evidence such as
commercial success, long-felt need, and the failure of others.
<i>Graham v. John Deere Co.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">383 U.S. 1</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C6EI?jcsearch=383%20us%201&amp;summary=yes#jcite">17-18</a>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C6EI?jcsearch=86%20supreme%20court%20684&amp;summary=yes#jcite">86 S.Ct. 684</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C6EI?jcsearch=15%20l%20ed%202d%20545&amp;summary=yes#jcite">15 L.Ed.2d 545</a> (1966). Similarly, nonstatutory
obviousness-type double patenting is a question of law with
underlying findings of fact. <i>In re Longi</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X4A97G?jcsearch=759%20f%202d%20887&amp;summary=yes#jcite">759 F.2d 887</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X4A97G?jcsearch=759%20f%202d%20887&amp;summary=yes#jcite">892</a> (Fed. Cir. 1985).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following a bench trial, we review the district court's
conclusions of law <i>de novo</i> and its findings of fact
for clear error. <i>Golden Blount, Inc. v. Robert H. Peterson</i>
<i>Co.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XN5BEJQNB5G0?jcsearch=365%20f%203d%201054&amp;summary=yes#jcite">365 F.3d 1054</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XN5BEJQNB5G0?jcsearch=365%20f%203d%201054&amp;summary=yes#jcite">1058</a> (Fed. Cir. 2004). A factual finding
is clearly erroneous if, despite some supporting evidence, we
are left with the definite and firm conviction that a mistake
has been made. <i>United States v. U.S. Gypsum Co.</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C1AJ?jcsearch=333%20us%20364&amp;summary=yes#jcite">333 U.S. 364</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C1AJ?jcsearch=333%20us%20364&amp;summary=yes#jcite">395</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C1AJ?jcsearch=68%20supreme%20court%20525&amp;summary=yes#jcite">68 S.Ct. 525</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X5C1AJ?jcsearch=92%20l%20ed%20746&amp;summary=yes#jcite">92 L.Ed. 746</a> (1948).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                    I
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We first address the Defendants' arguments that the district
court erred by failing to hold the asserted claims invalid for
obviousness under &sect; 103.<a HREF="#fn300" name="fnref_fn300">[fn3]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Defendants contend that aripiprazole would have been
obvious over the prior art <span CLASS="page_no" data-cite="102 uspq 2d 1737" data-cite-type="ReporterOfDecisions" data-cite-pageno="1737" data-primary-citation="102 U.S.P.Q.2d 1729">[**1737]</span> carbostyril derivative compounds at
the time aripiprazole was invented. They assert that the lead
compound analysis applied by the district court violates our
precedent and "fall[s] into a rigid obviousness analysis
precluded by <i>KSR.</i>" Br. Defs.Appellants Apotex,
at 35-36. In this regard, the Defendants allege that the court
erred by assuming that "only the
<span CLASS="page_no" data-cite="678 f 3d 1291" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1291" data-primary-citation="678 F.3d 1280">[*1291]</span> 
most obvious choice could serve as a lead." <i></i><cite>Id.
at 34</cite>. According to the Defendants, prior art compounds, including
the 2,3-dichloro propoxy, the unsubstituted butoxy, and
OPC-4392, were known to have antipsychotic activity, and it
would have been obvious to chemically modify them in the ways
necessary to make aripiprazole. Finally, they argue that
aripiprazole's properties and other secondary considerations do
not render aripiprazole nonobvious.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Otsuka, in response, argues that the district court correctly
rejected the Defendants' obviousness contentions, which are
based on improper hindsight bias. Otsuka points out that no
carbostyril derivative had been shown to effectively treat
schizophrenia as of the priority date of the &prime;<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X2G00C5120J?jcsearch=usp%205006528&amp;summary=yes#jcite">528 patent</a>.
Otsuka also contends that the district court did not require
proof that aripiprazole was the "most obvious" compound, but
rather evaluated all of the potential choices available to one
of ordinary skill and determined that the prior art did not
suggest that the unsubstituted butoxy, 2,3-dichloro propoxy, or
OPC-4392 would be suitable lead compounds. Otsuka also asserts
that secondary considerations support the court's conclusion of
nonobviousness.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the following reasons, we hold that the district court
correctly determined that the Defendants failed to prove by
clear and convincing evidence that the asserted <span CLASS="page_no" data-cite="2012 bl 111335 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> claims would
have been obvious under <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
            A. The District Court's "Lead Compound" Analysis
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914838" href="#headnote_pq2-dec_914838">[1]</a> In cases involving the patentability of a new chemical
compound, prima <i>facie</i> obviousness under the third
<i>Graham</i> factor generally turns on the structural
similarities and differences between the claimed compound and
the prior art compounds. <i>Daiichi Sankyo Co. v. Matrix</i>
<i>Labs., Ltd.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1E5GH8003?jcsearch=619%20f%203d%201346&amp;summary=yes#jcite">619 F.3d 1346</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1E5GH8003?jcsearch=619%20f%203d%201346&amp;summary=yes#jcite">1352</a> (Fed. Cir. 2010). The
Defendants assert that the district court; erred by employing a
"lead compound" analysis as part of its determination under the
third <i>Graham</i> factor. We reject that contention. New
compounds may be created from theoretical considerations rather
than from attempts to improve on prior art compounds. In this
case, however, the parties' arguments focus on selecting and
modifying particular prior art compounds, designated as lead
compounds.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Our case law demonstrates that whether a new chemical compound
would have been <i>prima facie</i> obvious over particular
prior art compounds ordinarily follows a two-part inquiry.
First, the court determines whether a chemist of ordinary skill
would have selected the asserted prior art compounds as lead
compounds, or starting points, for further development efforts.
<i>Eisai Co. v. Dr. Reddy's Labs., Ltd.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X198LVQ003?jcsearch=533%20f%203d%201353&amp;summary=yes#jcite">533 F.3d 1353</a>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X198LVQ003?jcsearch=533%20f%203d%201353&amp;summary=yes#jcite">1359</a> (Fed. Cir. 2008) ("[P]ost-<i>KSR</i>, a prima facie case
of obviousness for a chemical compound still, in general,
begins with the reasoned identification of a lead compound.").
A lead compound, as we have explained, is "a compound in the
prior art that would be most promising to modify in order to
improve upon its . . . activity and obtain a compound with
better activity." <i>Takeda Chem. Indus., Ltd. v. Alphapharm</i>
<i>Pty., Ltd.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X178166003?jcsearch=492%20f%203d%201350&amp;summary=yes#jcite">492 F.3d 1350</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X178166003?jcsearch=492%20f%203d%201350&amp;summary=yes#jcite">1357</a> (Fed. Cir. 2007). As such, a
lead compound is "a natural choice for further development
efforts." <i>Altana Pharma AG v. Teva Pharm. USA Inc.</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">566 F.3d 999</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">1008</a> (Fed. Cir. 2009). In recent cases involving
the alleged obviousness of a new chemical compound, the parties
have frequently focused upon the notion that a chemist must
select one or more lead compounds. <i>E.g., Daiichi</i>
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1E5GH8003?jcsearch=619%20f%203d%201346&amp;summary=yes#jcite">619 F.3d at 1352</a>; <i>Altana</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">566 F.3d at 1007</a>; <i>Procter</i>
<i>&amp; Gamble Co. v. Teva Pharm.</i>
<span CLASS="page_no" data-cite="678 f 3d 1292" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1292" data-primary-citation="678 F.3d 1280">[*1292]</span> 
<i>USA Inc.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d 989</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">994</a> (Fed. Cir. 2009);
<i>Eisai</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X198LVQ003?jcsearch=533%20f%203d%201353&amp;summary=yes#jcite">533 F.3d at 1357</a>; <i>Takeda</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X178166003?jcsearch=492%20f%203d%201350&amp;summary=yes#jcite">492 F.3d at 1357</a>; <i>Eli Lilly &amp; Co. v. Zenith Goldline Pharm.,</i>
<i>Inc.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X164AGG003?jcsearch=471%20f%203d%201369&amp;summary=yes#jcite">471 F.3d 1369</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X164AGG003?jcsearch=471%20f%203d%201369&amp;summary=yes#jcite">1379</a> (Fed. Cir. 2006); <i>Yamanouchi</i>
<i>Pharm. Co. v. Danbury Pharmacal, Inc.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3FMS5?jcsearch=231%20f%203d%201339&amp;summary=yes#jcite">231 F.3d 1339</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3FMS5?jcsearch=231%20f%203d%201339&amp;summary=yes#jcite">1345</a>
(Fed. Cir. 2000); <i>cf. Unigene Labs., Inc. v. Apotex,</i>
<i>Inc.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1G4JFM003?jcsearch=655%20f%203d%201352&amp;summary=yes#jcite">655 F.3d 1352</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1G4JFM003?jcsearch=655%20f%203d%201352&amp;summary=yes#jcite">1362</a> (Fed. Cir. 2011) ("[T]he term
`reference composition' is more appropriate than `lead
compound' when considering obviousness for a chemical
composition."). In such cases our analysis focuses on those
proposed lead compounds that <span CLASS="page_no" data-cite="102 uspq 2d 1738" data-cite-type="ReporterOfDecisions" data-cite-pageno="1738" data-primary-citation="102 U.S.P.Q.2d 1729">[**1738]</span> the alleged infringer has
attempted to prove, by clear and convincing evidence, that the
skilled artisan would have had a reason to select from the
panoply of known compounds in the prior art. <i>Daiichi</i>
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1E5GH8003?jcsearch=619%20f%203d%201346&amp;summary=yes#jcite">619 F.3d at 1354</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In determining whether a" chemist would have selected a prior
art compound as a lead, the analysis is guided by evidence of
the compound's pertinent properties. <i>See Eli Lilly</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X164AGG003?jcsearch=471%20f%203d%201369&amp;summary=yes#jcite">471 F.3d at 1378</a>; <i>In re Lain</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XABQ4E?jcsearch=747%20f%202d%20703&amp;summary=yes#jcite">747 F.2d 703</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XABQ4E?jcsearch=747%20f%202d%20703&amp;summary=yes#jcite">707</a>
(Fed. Cir. 1984). Such properties may include positive attributes
such as activity and potency, <i>Altana</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3L62003?jcsearch=566%20f%203d%20999&amp;summary=yes#jcite">566 F.3d at 1008</a>; <i>Eli Lilly</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X164AGG003?jcsearch=471%20f%203d%201369&amp;summary=yes#jcite">471 F.3d at 1379</a>; <i>Yamanouchi</i>
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3FMS5?jcsearch=231%20f%203d%201339&amp;summary=yes#jcite">231 F.3d at 1345</a>; adverse effects such as toxicity,
<i>Takeda</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X178166003?jcsearch=492%20f%203d%201350&amp;summary=yes#jcite">492 F.3d at 1358</a>, and other relevant
characteristics in evidence, <i>see Eisai</i>
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X198LVQ003?jcsearch=533%20f%203d%201353&amp;summary=yes#jcite">533 F.3d at 1358</a> (considering a prior art compound's lipophilicity and low
molecular <span CLASS="page_no" data-cite="2012 bl 111335 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> weight); <i>Pfizer, Inc. v. Apotex, Inc.</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d 1348</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">1363</a> (Fed. Cir. 2007) (considering the "strength,
solubility, and other known chemical characteristics" of a
prior art saltforming acid). Absent a reason or motivation
based on such prior art evidence, mere structural similarity
between a prior art compound and the claimed compound does not
inform the lead compound selection. <i>See Daiichi</i>
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1E5GH8003?jcsearch=619%20f%203d%201346&amp;summary=yes#jcite">619 F.3d at 1354</a>; <i>In re Dillon</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X32LO2?jcsearch=919%20f%202d%20688&amp;summary=yes#jcite">919 F.2d 688</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X32LO2?jcsearch=919%20f%202d%20688&amp;summary=yes#jcite">692</a>
(Fed. Cir. 1990) (en banc) ("[S]tructural similarity between
claimed and prior art subject matter, proved by combining
references or otherwise, <i>where the prior art gives reason</i>
<i>or motivation to make the claimed compositions</i>, creates a
<i>prima facie</i> case of obviousness." (emphasis added)).
Were it otherwise, the analysis would impermissibly rely upon
<i>ex post</i> reasoning. <i>See KSR Int'l Co. v. Teleflex,</i>
<i>Inc.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. 398</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">421</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=167%20l%20ed%202d%20705&amp;summary=yes#jcite">167 L.Ed.2d 705</a>
(2007) ("A factfinder should be aware, of course, of the
distortion caused by hindsight bias and must be cautious of
arguments reliant upon <i>ex post</i> reasoning.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The second inquiry in the analysis is whether the prior art
would have supplied one of ordinary skill in the art with a
reason or motivation to modify a lead compound to make the
claimed compound with a reasonable expectation of success.
<i>Take-da</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X178166003?jcsearch=492%20f%203d%201350&amp;summary=yes#jcite">492 F.3d at 1357</a> ("[I]n cases involving new
chemical compounds, it remains necessary to identify some
reason that would have led a chemist to modify a known compound
in a particular manner to establish prima facie obviousness of
a new claimed compound."); <i>Pfizer</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d at 1361</a>
("[T]he challenger of the patent [must] show by clear and
convincing evidence that a skilled artisan would have been
motivated to combine the teachings of the prior art references
to achieve the claimed invention, and that the skilled artisan
would have had a reasonable expectation of success in doing
so."); <i>Dillon</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X32LO2?jcsearch=919%20f%202d%20688&amp;summary=yes#jcite">919 F.2d at 692</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In keeping with the flexible nature of the obviousness inquiry,
the reason or motivation for modifying a lead compound may come
from any number of sources and need not necessarily be explicit
in the prior art. <i>Eisai</i> <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X198LVQ003?jcsearch=533%20f%203d%201353&amp;summary=yes#jcite">533 F.3d at 1357</a> (citing
<i>KSR</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 415</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>); <i>Aventis</i>
<i>Pharma Deutschland GmbH v. Lupin, Ltd.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X17KB8A003?jcsearch=499%20f%203d%201293&amp;summary=yes#jcite">499 F.3d 1293</a>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X17KB8A003?jcsearch=499%20f%203d%201293&amp;summary=yes#jcite">1301</a> (Fed. Cir. 2007). Again, pertinent properties guide the
analysis, for "it is the possession of promising useful
properties in a lead compound
<span CLASS="page_no" data-cite="678 f 3d 1293" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1293" data-primary-citation="678 F.3d 1280">[*1293]</span> 
that motivates a chemist to make structurally similar
compounds." <i>Daiichi</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1E5GH8003?jcsearch=619%20f%203d%201346&amp;summary=yes#jcite">619 F.3d at 1354</a> ("Potent and
promising activity in the prior art trumps mere structural
relationships."); <i>see also Eli Lilly</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X164AGG003?jcsearch=471%20f%203d%201369&amp;summary=yes#jcite">471 F.3d at 1378</a>
("[P]atentability for a chemical compound does not depend only
on structural similarity."); <i>In re Stemniski</i>
58 CCPA 1410, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XII2KN?jcsearch=444%20f%202d%20581&amp;summary=yes#jcite">444 F.2d 581</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XII2KN?jcsearch=444%20f%202d%20581&amp;summary=yes#jcite">586</a> (1971). As we have explained, "it is
sufficient to show that the claimed and prior art compounds
possess a `sufficiently close relationship . . . to create an
expectation,' in light of the totality of the prior art, that
the new compound will have `similar properties' to the old."
<i>Aventis</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X17KB8A003?jcsearch=499%20f%203d%201293&amp;summary=yes#jcite">499 F.3d at 1301</a> (quoting <i>Dillon</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X32LO2?jcsearch=919%20f%202d%20688&amp;summary=yes#jcite">919 F.2d at 692</a>); <i>see also In re Wilder</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X44UKR?jcsearch=563%20f%202d%20457&amp;summary=yes#jcite">563 F.2d 457</a>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X44UKR?jcsearch=563%20f%202d%20457&amp;summary=yes#jcite">460</a> (CCPA 1977).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914839" href="#headnote_pq2-dec_914839">[2]</a> In the present case, in assessing whether aripiprazole would
have been <i>prima facie</i> obvious in view of the prior art
compounds asserted by the Defendants, the district court
summarized the applicable law as requiring inquiry into
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  the hypothetical person of skill in the art's
  identification of a lead compound, <span CLASS="page_no" data-cite="2012 bl 111335 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> structural
  differences between the proposed lead compound and the
  claimed invention, motivation or teachings in the
  prior art to make the necessary changes to arrive at
  the claimed invention, and whether the person of skill
  in the art would have a reasonable expectation of
  success in making such structural changes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *16,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 U.S. Dist. LEXIS 132595,
at *52-53. We discern no error in the district court's
recitation of the applicable law. Moreover, the court did not
require, as the Defendants allege, that only "the most obvious
choice" could serve as the lead. Rather, the <span CLASS="page_no" data-cite="102 uspq 2d 1739" data-cite-type="ReporterOfDecisions" data-cite-pageno="1739" data-primary-citation="102 U.S.P.Q.2d 1729">[**1739]</span> district court
concluded that two compounds &mdash; clozapine and risperidone
&mdash; would have been considered viable lead compounds.
<i><cite>Id</cite>.</i> at *23-24, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 U.S. Dist. LEXIS 132595 at *76.
These were the only marketed antipsychotic compounds at the
time the present inventors began their work. They were the
natural and obvious lead compounds whose structures one would
have considered to modify to obtain improved antipsychotic
compounds. At the relevant time, there were no carbostyril
compounds that were marketed as antipsychotics or were publicly
known to have potent antipsychotic activity with minimal side
effects. Carbostyrils were thus not plausible lead compounds,
except in retrospect, and the district court did not clearly
err in concluding that they were not.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As for the Defendants' purported lead compounds, the district
court carefully considered each compound and correctly rejected
the contention that a skilled artisan would have selected those
compounds for further antipsychotic drug research efforts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                  B. The Unsubstituted Butoxy Compound
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In evaluating the differences between the claimed invention and
the prior art, the district court first considered the
unsubstituted butoxy compound disclosed in the prior art
&prime;416 patent and the Nakagawa declaration. The Defendants
contend that the court erred by finding that a skilled artisan
would not have selected the unsubstituted butoxy as a lead
compound for antipsychotic drug discovery. We disagree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914840" href="#headnote_pq2-dec_914840">[3]</a> As the court noted, the claims of the prior art &prime;416
patent explicitly disclose the unsubstituted butoxy as
producing an antihistaminic effect. This clear teaching
controls over the far more nebulous disclosure that the
trillions of carbostyril compounds encompassed by the
&prime;416 patent "have antihistaminic and central nervous
controlling effects." &prime;416 patent col.2 ll.50-51. As
explained by Dr. Bryan Roth, whom the court credited as an
expert in schizophrenia,
<span CLASS="page_no" data-cite="678 f 3d 1294" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1294" data-primary-citation="678 F.3d 1280">[*1294]</span> 
antipsychotic drug discovery, and psychopharmacology, one
of ordinary skill in the art would not have understood the
&prime;416 patent's "laundry list" of potential central nervous
system controlling effects to mean that every carbostyril
derivative disclosed in the &prime;416 patent is a potential
antipsychotic. <i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *8, *10,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 U.S. Dist. LEXIS 132595, at *26, *31.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Nakagawa declaration similarly fails to support the
Defendants' contentions. As an initial matter, Otsuka argues in
a footnote to its brief that the Nakagawa declaration is not
eligible as prior art because the Defendants failed to prove
that a chemist <span CLASS="page_no" data-cite="2012 bl 111335 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> seeking to develop a new antipsychotic drug
would have consulted the unindexed file history of the prior
art &prime;416 patent in the course of his or her research. Br.
Pl.-Appellee Otsuka, at 24 n. 1. Arguments raised only in
footnotes, however, are waived. <i>SmithKline Beecham Corp. v.</i>
<i>Apotex Corp.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1471AA003?jcsearch=439%20f%203d%201312&amp;summary=yes#jcite">439 F.3d 1312</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1471AA003?jcsearch=439%20f%203d%201312&amp;summary=yes#jcite">1320</a> (Fed. Cir. 2006). Although
we may exercise our discretion to consider improperly raised
arguments, we decline to do so here. <i>See Becton Dickinson</i>
<i>&amp; Co. v. C.R. Bard, Inc.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3554U?jcsearch=922%20f%202d%20792&amp;summary=yes#jcite">922 F.2d 792</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3554U?jcsearch=922%20f%202d%20792&amp;summary=yes#jcite">800</a>
(Fed. Cir. 1990). We therefore assume, without deciding, that the
Nakagawa declaration qualifies as prior art.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although Nakagawa's mouse jumping data "could be indicative of
potential anti-psychotic activity to the skilled artisan,"
<i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *10,
<a>2010 U.S. Dist. LEXIS 132595</a>,
at *34, that alone does not resolve the matter. Rather,
we must consider the contents of the declaration as a whole, as
the district court correctly did. In doing so, we focus in
particular on the compounds' disclosed properties because, as
the district court found, "[g]enerally, a skilled artisan would
be attracted to the most potent compounds in selecting a lead
compound for development." <i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id. at *17</a>,
<a>2010 U.S. Dist. LEXIS 132595</a> at *54; <i>see also Daiichi</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1E5GH8003?jcsearch=619%20f%203d%201346&amp;summary=yes#jcite">619 F.3d at 1354</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Of the nine carbostyril test compounds for which the Nakagawa
declaration supplied mouse jumping data, the unsubstituted
butoxy was inferior to four other test compounds and thus "was
only of middling potency." <i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at
*20, <a>2010 U.S. Dist. LEXIS 132595</a>, at *65. Significantly, the
four more potent test compounds were all propoxy-linked,
including Compound 44, which, with an ED <sub>50</sub> of 0.53
milligrams per kilogram, "was by far the most potent of the
compounds tested." <i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id. at *17</a>,
<a>2010 U.S. Dist. LEXIS 132595</a>
at *54. One of the Defendants' own experts conceded that
the activity of Compound 44 was "striking," and Dr. Roth
testified that if a skilled artisan were to select any compound
from the Nakagawa declaration, it would be Compound 44.
<i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id</a>.</i>, at *17, *17-18, <a>2010 U.S. Dist. LEXIS 132595</a> at
*54, *56. The Defendants do not allege obviousness over the
structurally dissimilar Compound 44, which, unlike
aripiprazole, has a propoxy linker connected at the 5-position
of its carbostyril core and a 2-ethoxy substituent on its
phenyl ring. As the district court found, the Nakagawa
declaration would, if anything, have taught one of ordinary
skill to select a 5-linked propoxy carbostyril derivative as a
lead compound. <i>See <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">id</a>.</i>, at *18,
<a>2010 U.S. Dist. LEXIS 132595</a>
at *57 (comparing the ED 60 value of 2.1 for a <span CLASS="page_no" data-cite="102 uspq 2d 1740" data-cite-type="ReporterOfDecisions" data-cite-pageno="1740" data-primary-citation="102 U.S.P.Q.2d 1729">[**1740]</span> 5-linked
unsubstituted propoxy and the ED <sub>50</sub> value of 9.3 for
a 7-linked unsubstituted propoxy and finding that this
"significant" difference "would teach the skilled artisan the
superiority of 5-linked propoxy compounds over 7-linked propoxy
compounds").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Thus, neither the &prime;416 patent nor the Nakagawa
declaration supports the Defendants' position that one of
ordinary skill would have selected the prior art unsubstituted
<span CLASS="page_no" data-cite="678 f 3d 1295" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1295" data-primary-citation="678 F.3d 1280">[*1295]</span> 
butoxy compound as a lead compound for further
antipsychotic research.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                  C. The 2,3-Dichloro Propoxy Compound
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  According to the Defendants, the district court erred by
failing to find that aripiprazole would have been obvious over
the SE &prime;945 application, which taught that the
2,3-dichloro propoxy compound had antipsychotic activity. We
disagree. The Defendants' argument "strains the scope <span CLASS="page_no" data-cite="2012 bl 111335 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> of the SE
&prime;945 application." <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id</a>.</i> at *20,
<a>2010 U.S. Dist. LEXIS 132595</a>
at *62. As the district court correctly found, the
SE &prime;945 application lists the 2,3-dichloro propoxy
compound "as one among hundreds of examples that may be useful
for an extensive list of potential central nervous system
controlling activities," <i>id.</i>, and fails to tie the
2,3-dichloro propoxy to any meaningful suggestion of
antipsychotic activity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914841" href="#headnote_pq2-dec_914841">[4]</a> The Defendants, citing <i>Pfizer</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X16HK1U003?jcsearch=480%20f%203d%201348&amp;summary=yes#jcite">480 F.3d 1348</a>, allege
that the SE &prime;<cite>945 application</cite>'s generic disclosure "is all
that is required for obviousness." Br. Defs.-Appellants Apotex,
at 37. In <i>Pfizer</i>, this court held that the claimed
amlodipine besylate salt would have been obvious in view of the
known chemical structure of amlodipine and a prior art group of
salt-forming anions including benzene sulphonate (which
combines with amlodipine to form the besylate salt).
<i>Pfizer</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X16HK1U003?jcsearch=480%20F.3d%201348&amp;summary=yes#jcite">480 F.3d at 1372</a>. This court premised its
conclusion on findings that the prior art not only provided
"ample motivation to narrow the [prior art] genus of . . .
salt-forming anions . . . to a few [species]," <i>id.</i>
at 1363, but also "predicted the results," <i>id.</i> at 1367.
In the present case, in contrast to <i>Pfizer</i>, the
Defendants failed to make an analogous showing. The district
court thus correctly found that one of ordinary skill in the
art would not have selected the 2,3-dichloro propoxy compound
as a lead compound for further antipsychotic research.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Furthermore, as Otsuka points out, the Defendants' theory that
aripiprazole would have been obvious over the unsubstituted
butoxy and the 2,3-dichloro propoxy rested in large part upon
an asserted "bracketing theory" &mdash; <i>i.e.</i>, that one
would have combined those two asserted compounds to arrive at
aripiprazole, which shares some structural features of both.
The district court found that the Defendants' theory
constituted "an improper hindsight analysis." <i>Otsuka</i>,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *20, <a>2010 U.S. Dist. LEXIS 132595</a>, at *64.
The Defendants do not on appeal challenge the district court's
finding or re-assert their bracketing theory. Accordingly, we
conclude that the Defendants failed to prove by clear and
convincing evidence that aripiprazole would have been obvious
over the 2,3-dichloro propoxy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               D. OPC-4392
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914842" href="#headnote_pq2-dec_914842">[5]</a> The Defendants also assert that the district court erred by
rejecting OPC-4392 as a lead compound. Again, we dis-agree. The
Defendants rely selectively on the disclosure in Murasaki 1987
that OPC-4392 was "an antipsychotic drug," J.A. 5907, and the
fact that OPC-4392 proceeded to Phase II clinical trials. Taken
as a whole, however, the prior art taught away from using
OPC-4392 as a starting point for further antipsychotic
research.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For example, Murasaki 1987 teaches that "the antipsychotic
action [of OPC-4392] was not strong." <i>Id.</i> Based on
that teaching, together with other prior art of record that
focuses only on the effects of OPC-4392 on schizophrenia's
negative symptoms, a skilled artisan would have concluded that
OPC-4392 did not treat positive symptoms. <i>Otsuka</i>,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *21-22, <a>2010 U.S. Dist. LEXIS 132595</a>, at *68-69.
The district court also credited the testimony of one of the
Defendants' witnesses, who stated that clinical
<span CLASS="page_no" data-cite="678 f 3d 1296" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1296" data-primary-citation="678 F.3d 1280">[*1296]</span> 
studies of OPC-4392 showed that it "lacked [an]
antipsychotic component." <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id</a>.</i> at *21,
<a>2010 U.S. Dist. LEXIS 132595</a> at *68. Furthermore, <span CLASS="page_no" data-cite="2012 bl 111335 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> Murasaki 1987 taught that
"the strength of the activating action [of OPC-4392] stood
out," J.A. 5907, a property that Dr. Roth testified would have
been a "red flag" indicating that the drug was likely to cause
patients to act out on their delusions and hallucinations.
<i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *21-22,
<a>2010 U.S. Dist. LEXIS 132595</a>, at *69. Another prior art reference, Murasaki
1988, taught that OPC-4392, even at a "very low dose,"
<i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">id. at *12</a>, <a>2010 U.S. Dist. LEXIS 132595</a> at *41,
caused "severe" side effects, J.A. 10401. In light of the
totality of the evidence before the district court, we perceive
no clear error in the conclusion that OPC-4392 was "considered
a failure insofar as it did not treat the positive symptoms of
schizophrenia and was not well-tolerated in modest doses."
<i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *22,
<a>2010 U.S. Dist. LEXIS 132595</a>,
at *70. The court thus did not err in concluding that
one of ordinary skill in the art would not have selected
OPC-4392 <span CLASS="page_no" data-cite="102 uspq 2d 1741" data-cite-type="ReporterOfDecisions" data-cite-pageno="1741" data-primary-citation="102 U.S.P.Q.2d 1729">[**1741]</span> as a lead compound for further antipsychotic research.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Even assuming that one would have selected OPC-4392 as a lead
compound, the district court found that the Defendants failed
to prove that the prior art would have directed one to make the
various modifications necessary to convert OPC-4392 into
aripiprazole. Those modifications include: (1) converting
OPC-4392's carbostyril core into a dihydrocarbostyril; (2)
changing OPC-4392's propoxy linker to a butoxy; and (3)
replacing OPC-4392's 2-methyl and 3-methyl groups with 2-chloro
and 3-chloro substituents. On appeal, the Defendants rely in
large part on the inventors' and Otsuka's own development
efforts in an attempt to prove that aripiprazole would have
been obvious. <i>E.g.</i>, Br. Defs.-Appellants Apotex,
at 46-47 (arguing that Otsuka's aripiprazole development involved
a "short timeline" and only "took a few months"). Those
arguments cannot trump the district court's careful fact
finding, however. The inventor's own path itself never leads to
a conclusion of obviousness; that is hindsight. What matters is
the path that the person of ordinary skill in the art would
have followed, as evidenced by the pertinent prior
art. <i>See</i> <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103(a)&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>(a) ("Patentability shall not
be negatived by the manner in which the invention was made.");
<i>Life Techs., Inc. v. Clontech Labs., Inc.</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3FJLJ?jcsearch=224%20f%203d%201320&amp;summary=yes#jcite">224 F.3d 1320</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3FJLJ?jcsearch=224%20f%203d%201320&amp;summary=yes#jcite">1325</a> (Fed. Cir. 2000) ("[T]he path that leads an inventor
to the invention is expressly made irrelevant to patentability
by statute."). We therefore agree with the district court that
the Defendants failed to provide clear and convincing evidence
that the skilled artisan would have known how to modify OPC4392
to increase antipsychotic activity. <i>Otsuka</i>,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *22, <a>2010 U.S. Dist. LEXIS 132595</a>, at *70.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                              E. Conclusion
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In summary, the district court's careful analysis exposed the
Defendants' obviousness case for what it was &mdash; a poster
child for impermissible hindsight reasoning. Because we agree
with the district court that the Defendants failed to prove
that claim 12 of the &prime;<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X2G00C5120J?jcsearch=usp%205006528&amp;summary=yes#jcite">528 patent</a> would have been
<i>prima facie</i> obvious over the asserted prior art
compounds, we need not address the court's findings regarding
objective evidence of nonobviousness. In addition, because the
Defendants' arguments for obviousness of dependent claims 17
and 23 rely on a determination of obviousness for independent
claim 12, we <span CLASS="page_no" data-cite="2012 bl 111335 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> need not separately analyze the court's finding
that the Defendants failed to prove invalidity for the asserted
dependent claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                                   II
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We now turn to the Defendants' contention that the district
court erred by
<span CLASS="page_no" data-cite="678 f 3d 1297" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1297" data-primary-citation="678 F.3d 1280">[*1297]</span> 
failing to hold the asserted claims of the &prime;<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X2G00C5120J?jcsearch=usp%205006528&amp;summary=yes#jcite">528
patent</a> invalid for nonstatutory obviousness-type double
patenting in view of the unsubstituted butoxy compound of claim
13 of the &prime;<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X21OC840HGJ?jcsearch=usp%204734416&amp;summary=yes#jcite">416 patent</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  An inventor may obtain "a patent" for an invention pursuant to
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVA003?jcsearch=35%20usc%20101&amp;summary=yes#jcite">35 U.S.C. &sect; 101</a>; the statute thus "permits only one patent
to be obtained for a single invention." <i>In re Lonardo</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XACAAK?jcsearch=119%20f%203d%20960&amp;summary=yes#jcite">119 F.3d 960</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XACAAK?jcsearch=119%20f%203d%20960&amp;summary=yes#jcite">965</a> (Fed. Cir. 1997). The double patenting doctrine
"precludes one person from obtaining more than one valid patent
for either (a) the `same invention,' or (b) an `obvious'
modification of the same invention." <i>Longi</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X4A97G?jcsearch=759%20f%202d%20887&amp;summary=yes#jcite">759 F.2d at 892</a>. Nonstatutory double patenting is a judicially created
doctrine grounded in public policy that "prevent[s] the
extension of the term of a patent, even where an express
statutory basis for the rejection is missing, by prohibiting
the issuance of the claims in a second patent not patentably
distinct from the claims of the first patent." <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XACAAK?jcsearch=119%20F.3d%20960&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914843" href="#headnote_pq2-dec_914843">[6]</a> As an initial matter, the parties disagree over the legal test
for non-statutory double patenting. Otsuka contends that there
is no difference between obviousness under <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a> and
obviousness-type double patenting. That is not entirely
correct. We have noted that "a double patenting of the
obviousness type rejection is analogous to [a failure to meet]
the non-obviousness requirement of <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>."
<i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XACAAK?jcsearch=119%20F.3d%20960&amp;summary=yes#jcite">Id. at 892</a> n. 4 (internal quotation marks omitted).
Important differences remain, however. The patent principally
underlying the double patenting rejection need not be prior
art. <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XACAAK?jcsearch=119%20F.3d%20960&amp;summary=yes#jcite">Id</a>.</i> Moreover, when analyzing obviousness-type
double patenting in cases involving claimed chemical compounds,
the issue is not whether a skilled artisan would have selected
the earlier compound as a lead compound. That is so because the
analysis must necessarily focus on the earlier claimed compound
over which double patenting has been alleged, lead compound or
not. <i>See Ortho Pharma. Corp. v. Smith</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3579Q?jcsearch=959%20f%202d%20936&amp;summary=yes#jcite">959 F.2d 936</a>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X3579Q?jcsearch=959%20f%202d%20936&amp;summary=yes#jcite">943</a> (Fed. Cir. 1992) ("[I]t is the claims that are compared when
assessing double patenting.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Defendants assert that, unlike an analysis under <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a>,
the test for obviousness-type double patenting never asks
whether the prior art would have supplied a motivation to
<span CLASS="page_no" data-cite="102 uspq 2d 1742" data-cite-type="ReporterOfDecisions" data-cite-pageno="1742" data-primary-citation="102 U.S.P.Q.2d 1729">[**1742]</span> modify the earlier claimed compound. That is also incorrect.
Unless the earlier claim anticipates the later claim under
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVC003?jcsearch=35%20U.S.C.%20%20102&amp;summary=yes#jcite">&sect; 102</a>, the question whether the two claimed compounds are
"patentably distinct" implicates the question of obviousness
under <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a>, <i>Longi</i> <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X4A97G?jcsearch=759%20f%202d%20887&amp;summary=yes#jcite">759 F.2d at 892</a>, which in the
chemical context requires identifying some reason that would
have led a chemist to modify the earlier compound to make the
later compound with a reasonable expectation of success,
<i>see Takeda</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X178166003?jcsearch=492%20f%203d%201350&amp;summary=yes#jcite">492 F.3d at 1357</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X178166003?jcsearch=492%20f%203d%201350&amp;summary=yes#jcite">1361</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Defendants rely on <i>Geneva Pharm., Inc. v.</i>
<i>GlaxoSmithKline PLC</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XF7HAM?jcsearch=349%20f%203d%201373&amp;summary=yes#jcite">349 F.3d 1373</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XF7HAM?jcsearch=349%20f%203d%201373&amp;summary=yes#jcite">1377</a> n. 1
(Fed. Cir. 2003), which states in a footnote that "[o]bviousness
requires inquiry into a motivation to modify the prior art;
nonstatutory double patenting does not." <i>Geneva</i>,
however, involved non-statutory double patenting based on
anticipation, not obviousness. <span CLASS="page_no" data-cite="2012 bl 111335 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XF7HAM?jcsearch=349%20F.3d%201373&amp;summary=yes#jcite">Id</a>.</i> ("This
genus-species relationship makes the claims patentably
indistinct, because the earlier species . . . anticipates the
later genus. . . ."). For anticipation, of course, motivation
in the prior art is unimportant. <i>See, e.g., Callaway Golf</i>
<i>Co. v. Acushnet Co.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1Q6L6VRNG82?jcsearch=576%20f%203d%201331&amp;summary=yes#jcite">576 F.3d 1331</a>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1Q6L6VRNG82?jcsearch=576%20f%203d%201331&amp;summary=yes#jcite">1347</a> (Fed. Cir. 2009)
(noting that, in an "anticipation argument, . . . motivation to
combine is not an issue"). The statement from <i>Geneva</i>
was later recited in dictum in <i>Procter &amp; Gamble Co. v.</i>
<i>Teva Pharm. USA Inc.</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d 989</a> (Fed. Cir. 2009), in
which we concluded under <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20U.S.C.%20%20103&amp;summary=yes#jcite">&sect; 103</a> that there would have been
no motivation
<span CLASS="page_no" data-cite="678 f 3d 1298" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1298" data-primary-citation="678 F.3d 1280">[*1298]</span> 
to modify the prior art compound, <i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3GOU003?jcsearch=566%20F.3d%20989&amp;summary=yes#jcite">id. at 995</a>, and
then stated: "Having concluded that [the asserted compound] was
not obvious under <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XEIVVE003?jcsearch=35%20usc%20103&amp;summary=yes#jcite">35 U.S.C. &sect; 103</a>, we <i>similarly</i>
<i>conclude</i> that the [asserted] patent is not invalid for
obviousness-type double patenting," <i>id.</i> at 999
(emphasis added). Contrary to the Defendants' arguments,
neither <i>Geneva</i> nor <i>Procter &amp; Gamble</i>
stands for the proposition that, in considering whether one
compound is an obvious variant of another for purposes of
nonstatutory double patenting, analyzing the compound of the
prior claim for a reason or motivation to modify is irrelevant.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We therefore reject the Defendants' contention that the
district court legally erred by relying in part on its findings
under &sect; 103 in its subsequent double patenting analysis.
The court in this case applied the correct test for
non-statutory obviousness-type double patenting: In the context
of claimed chemical compounds, an analysis of nonstatutory
obviousness-type double patenting &mdash; like an analysis
under &sect; 103 &mdash; entails determining, <i>inter</i>
<i>alia</i>, whether one of ordinary skill in the art would have
had reason or motivation to modify the earlier claimed compound
to make the compound of the asserted claim with a reasonable
expectation of success. There is no other way to consider the
obviousness of compound B over compound A without considering
whether one of ordinary skill would have had reason to modify A
to make B. That is traditional obviousness analysis.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Turning to the particulars of the district court's decision on
nonstatutory double patenting, the Defendants contend that the
court improperly treated claim 13 of the &prime;416 patent in
isolation without considering prior art, such as the Nakagawa
declaration, which would have taught a skilled artisan to
substitute a phenyl ring with chlorine atoms at the 2- and
3-positions to make aripiprazole. Otsuka, in response, argues
that the court, after considering the Nakagawa declaration in
detail, correctly concluded that aripiprazole was not an
obvious variant of the unsubstituted butoxy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <a id="headnote_ref_pq2-dec_914844" href="#headnote_pq2-dec_914844">[7]</a> We agree with the district court that the asserted claims are
not invalid for nonstatutory double patenting. As we explained
above, aripiprazole differs structurally from the unsubstituted
butoxy of claim 13 of the &prime;416 patent. Aripiprazole has
chlorine substituents at the 2 and 3 positions of its phenyl
ring, whereas the unsubstituted butoxy has hydrogens at those
positions &mdash; <i>i.e.</i>, it is "unsubstituted." In its
double patenting analysis, the court determined "that the prior
art, including the Nakagawa Declaration, . . . <span CLASS="page_no" data-cite="2012 bl 111335 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> did not teach
the person of ordinary skill in the art to pursue a
2,3-dichloro substitution on the phenyl ring to achieve
antipsychotic activity." <i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at
*29, <a>2010 U.S. Dist. LEXIS 132595</a>, at *90-91; <i>see also</i>
<i></i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">id. at *20</a>, <a>2010 U.S. Dist. LEXIS 132595</a> at *64. The
evidence before the district court supports this finding. For
example, the court credited evidence demonstrating the high
degree of unpredictability in anti-psychotic drug discovery as
of the priority date. <i><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">Id</a>.</i> at *15, *19,
<a>2010 U.S. Dist. LEXIS 132595</a>
at *48, *61. Experts testified that the discovery
of new antipsychotic drugs in the 1980s was "very
unpredictable," J.A. 30660, and that antipsychotic research at
that time was "notoriously un-successful," J.A. 30453. As
<i>KSR</i> makes clear, predictability is a vital
consideration in the obviousness analysis. <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=550%20us%20398&amp;summary=yes#jcite">550 U.S. at 421</a>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XRIK7VQNB5G0?jcsearch=127%20supreme%20court%201727&amp;summary=yes#jcite">127 S.Ct. 1727</a>; <i>see also Procter &amp; Gamble</i>,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1B3GOU003?jcsearch=566%20f%203d%20989&amp;summary=yes#jcite">566 F.3d at 996</a> ("[T]o the extent an art is unpredictable, as the chemical
arts often are, <i>KSR's</i> focus on . . . `identified,
predictable solutions' may present a difficult hurdle because
potential solutions are less likely to be genuinely
<span CLASS="page_no" data-cite="102 uspq 2d 1743" data-cite-type="ReporterOfDecisions" data-cite-pageno="1743" data-primary-citation="102 U.S.P.Q.2d 1729">[**1743]</span> predictable." (quoting <i>Eisai</i>, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X198LVQ003?jcsearch=533%20f%203d%201353&amp;summary=yes#jcite">533 F.3d at 1359</a>)).
<span CLASS="page_no" data-cite="678 f 3d 1299" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1299" data-primary-citation="678 F.3d 1280">[*1299]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As the district court correctly held, the prior art would not
have provided a skilled artisan with a reason to make the
necessary structural changes to the unsubstituted butoxy to
yield aripiprazole. <i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *29,
<a>2010 U.S. Dist. LEXIS 132595</a>, at *91. The Defendants posit that
substitution with chlorine atoms at the 2- and 3-positions of
the phenyl ring "would have been a logical and routine
modification." Br. Defs.-Appellants Apotex, at 66. The evidence
indicates otherwise. The Nakagawa declaration neither disclosed
nor would have suggested a 2,3-dichloro substituted
antipsychotic compound. <i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at
*19-20, <a>2010 U.S. Dist. LEXIS 132595</a>, at *62; J.A. 30689. And,
as we noted above, although other prior art including the SE
&prime;945 application disclosed 2,3-dichloro substituted
compounds, those references failed to tie that disclosure to
any meaningful suggestion of antipsychotic activity.
<i>Otsuka</i>, [<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at * 19-20,
<a>2010 U.S. Dist. LEXIS 132595</a>,
at *62. As Dr. David Nichols, an expert in both
medicinal chemistry and pharmacology, testified at trial:
"There was no known antipsychotic drug, successful or
otherwise, that had those two particular [chlorine]
substituents arranged in a 2,3 . . . orientation," and,
further, "[t]here's no teaching that suggests that a
dichlorination pattern like that would lead to a safe atypical
antipsychotic, or even an antipsychotic, period, atypical or
otherwise." J.A. 30688-89. In short, we perceive no clear error
in the district court's finding that one of ordinary skill
would not have been motivated to pursue a 2,3-dichloro
substitution on the phenyl ring as would have been required to
convert the unsubstituted butoxy to aripiprazole.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, the nonstatutory double patenting issue in this case
is not, as the Defendants argue, controlled by <i>In re</i>
<i>Zickendraht</i>, 50 CCPA 1529, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XIE6EV?jcsearch=319%20f%202d%20225&amp;summary=yes#jcite">319 F.2d 225</a> (1963). In
<i>Zickendraht</i>, one of our predecessor courts reviewed a
decision of the Board of Patent Appeals and Interferences (the
"Board") rejecting a claimed metalliferous azodyestuff compound
for nonstatutory double patenting over a similar compound
claimed in an issued patent. The two compounds were identical
but for the presence or absence of a methyl group. <i>Id.</i>
at 1534, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XIE6EV?jcsearch=319%20f%202d%20225&amp;summary=yes#jcite">319 F.2d 225</a>. In affirming <span CLASS="page_no" data-cite="2012 bl 111335 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> the Board's rejection, the
<i>Zickendraht</i> court noted that "[i]t has not been shown
that this [chemical] difference has any effect on the dyeing
characteristics of the compound." <i>Id.</i> at 1531,
<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XIE6EV?jcsearch=319%20f%202d%20225&amp;summary=yes#jcite">319 F.2d 225</a>. The court also pointed out that the earlier "patent
disclosure would suggest to one skilled in the art" reacting
particular starting components, which "should result in
production of the dye claimed" in the pending application.
<i>Id.</i> at 1532, <a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/XIE6EV?jcsearch=319%20f%202d%20225&amp;summary=yes#jcite">319 F.2d 225</a>. Unlike in
<i>Zickendraht</i>, the evidence here not only demonstrates
the unpredictability of minor structural changes on a
compound's anti-psychotic properties, but also indicates that
the prior art would not have provided the skilled artisan with
a reason to make the necessary structural changes to the
unsubstituted butoxy to yield aripiprazole. <i>Otsuka</i>,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *19, *29, <a>2010 U.S. Dist. LEXIS 132595</a>, at
*61, *91. <i>Zickendraht</i>, therefore, is distinguishable
from the present case.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Because we agree with the district court that the prior art
would not have provided one of ordinary skill with a reason or
motivation to make aripiprazole from the unsubstituted butoxy
compound, we need not examine Otsuka's evidence of secondary
considerations of nonobviousness. Moreover, the Defendants do
not advance separate double patenting arguments for the
asserted dependent claims of the &prime;528 patent. We
therefore conclude that the district court correctly determined
that all of the asserted claims of the &prime;528 patent are
not invalid for nonstatutory obviousness-type
<span CLASS="page_no" data-cite="678 f 3d 1300" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1300" data-primary-citation="678 F.3d 1280">[*1300]</span> 
double patenting over claim 13 of the &prime;416 patent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the foregoing reasons, we <i>affirm</i> the judgment of
the district court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  AFFIRMED
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> The Defendants also asserted an ultimately unsuccessful
inequitable conduct defense and counterclaim, which are not at
issue on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> Elsewhere in its opinion the district court referred to
Compound 39 as "OPC-4139." <i>See Otsuka</i>,
[<a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1EK3A8003?jcsearch=2010%20BL%20270509&amp;summary=yes#jcite">2010 BL 270509</a>], 2010 WL 4596324, at *13, <a>2010 U.S. Dist. LEXIS 132595</a>, at *42.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> Defendants-Appellants Apotex Inc. and Apotex Corp.
submitted one set of appellate briefs addressing the issues of
&sect; 103 obviousness and nonstatutory double patenting.
Defendants-Appellants Teva Pharmaceuticals USA, Inc., Barr
Laboratories, Inc., and Barr Pharmaceuticals, Inc., submitted
another set of briefs that addressed only nonstatutory double
patenting, but joined in full the principal and reply briefs
filed by Apotex. For purposes of this opinion we will refer to
the arguments in both sets of briefs as the Defendants'
arguments.
</p></div>
<!--BBLS DD 1707908530179-->

</div>
</td>
<td align='left' class='fluidRightColumn ' id='fluid_right_column' valign='top'>
<div class='clearfix printHide sideBar'>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HMJKG003/history">Direct History (4)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1HMJKG003/analysis">Case Analysis (11)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HMJKG003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
9
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1HMJKG003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
2
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Pharmaceuticals</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1Q6LG62MD82">11-01127 (Fed. Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/fcd395334c11872aa0a85ec182223ddd/document/X1Q6LG62MDO2">11-01126 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Patent Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
</td>
</tr>
</table>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/fcd395334c11872aa0a85ec182223ddd/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "fcd395334c11872aa0a85ec182223ddd";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY21b48c&previousPageId=&previousActivityInstanceId=ENTITY4d582b&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:47:41-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1HMJKG003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY4d582b&previousPageId=&previousActivityInstanceId=ENTITYbd5f3c&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:47:38-05:00';
FLUID_LAYOUT="true";
FULL_DOC_ID = 'X1HMJKG003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1HMJKG003";
$('#page_loader').show().spin();
JUDGE_IDS=["15753020","1718421","4283465"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
